ArticleOPEN ACCESS

R-CHOP in NLPHL: Who should receive it?

Blood
DOI: 10.1182/blood-2017-05-786301
1Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, Fanale and colleagues report promising treatment results for patients with newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) (see figure).1

Cite

CITATION STYLE

APA

Eichenauer, D. A., & Engert, A. (2017, July 27). R-CHOP in NLPHL: Who should receive it? Blood. American Society of Hematology. https://doi.org/10.1182/blood-2017-05-786301

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free